, Tracking Stock Market Picks
Enter Symbol:
Poniard Pharmaecuticals, Inc. (PARD) [hlAlert]

down 99.95 %

Poniard Pharmaecuticals, Inc. (PARD) rated Buy with price target $4 by Brean Murray

Posted on: Tuesday,  Apr 27, 2010  1:25 PM ET by Brean Murray

Brean Murray rated Buy Poniard Pharmaecuticals, Inc. (OTCBB: PARD) on 04/27/2010. Previously Brean Murray rated Buy Poniard Pharmaecuticals, Inc. (OTCBB: PARD) on
07/02/2009., when the stock price was $263.60. Since then, Poniard Pharmaecuticals, Inc. has lost 99.95% as of 08/27/2015's recent price of $0.12.
If you would have followed the previous Brean Murray's recommendation on PARD, you would have lost 99.95% of your investment in 2247 days.

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of cancer therapy products. Its lead product candidate is picoplatin, a platinum-based cancer therapy. An intravenous chemotherapeutic agent, picoplatin is designed to overcome platinum resistance in the treatment of solid tumors. The Company initiated a Phase III SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in small cell lung cancer. The Company is also conducting separate Phase I/II studies of picoplatin in the treatment of patients with metastatic colorectal cancer and hormone-refractory prostate cancer. NeoRx Manufacturing Group, Inc. is a wholly owned subsidiary of the Company.

Our equity research department is focused on fundamental analysis across the universe of over 200 small/mid cap stocks in our five target sectors. We are committed to providing proprietary action-oriented research to our institutional clients. Small cap growth focus. Our primary area of concentration is growth stocks with market capitalization of $200 million to $5 billion. Global perspective. We are covering U.S. listed stocks for companies domiciled in the U.S., China, Europe and Latin America, with our biggest concentration in the US and China. We were one of the first banks to aggressively expand our research to China and we believe we created one of the premier research franchises in small cap, U.S. listed Chinese companies to complement our strong domestic coverage. Disciplined stock selection. Our research analysts are focused on performing extensive bottoms up due diligence on companies under our coverage by leveraging their industry and management contacts. By combining our bottoms up work with our sector views we seek to generate a consistent flow of high conviction ideas for our clients. Diversified coverage. Our areas of expertise include technology, consumer, healthcare, resources and China small cap. We provide our clients with company-specific as well as sector-specific research across our target sectors.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/27/2010 1:25 PM Buy
48.40 160.00
as of 12/31/2010
1 Week up  18.51 %
1 Month up  77.77 %
3 Months up  10.34 %
1 YTD down  -65.02 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/2/2009 8:25 AM Buy
263.60 440.00
7/2/2009 8:25 AM Buy
263.60 440.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy